AmberJean P. Hansen, MPH, CCRP
she/her/hers
Research Associate 2 HSSCards
About
Research
Publications
2024
Risk of Clade II Mpox Associated with Intimate and Nonintimate Close Contact Among Men Who Have Sex with Men and Transgender Adults — United States, August 2022–July 2023
Chard A, Dalton A, Diallo A, Moulia D, Deputy N, Zecca I, Quilter L, Kachur R, McCollum A, Rowlands J, Britton A, Fisher R, Chai S, Licherdell E, Still W, Morris A, Castilho J, Markus T, Morrow A, Danza P, Hansen A, Ali S, Wegner C, Weber R, Betancourt G, Zipprich J, Sutton M, Pathela P, Hawkins S, Wendel K, Feldstein L. Risk of Clade II Mpox Associated with Intimate and Nonintimate Close Contact Among Men Who Have Sex with Men and Transgender Adults — United States, August 2022–July 2023. MMWR Morbidity And Mortality Weekly Report 2024, 73: 896-902. PMID: 39388387, PMCID: PMC11466375, DOI: 10.15585/mmwr.mm7340a2.Peer-Reviewed Original ResearchConceptsCondomless receptive anal sexReceptive anal sexAnal sexUnited StatesCase-patientsControl patientsAssociated with sexual contactSex practicesSexually active personsTransgenderAssociated with transmissionSexual contactAdjusted oddsMSMMenVaccination coverageActive personsNonintimatesVaccinePatientsMpoxVaccine promotionMultifaceted approachSexIntimateBarriers to the Uptake of Tickborne Disease Prevention Measures: Connecticut, Maryland 2016-2017
Hansen A, Wilkinson M, Niesobecki S, Rutz H, Meek J, Niccolai L, Hinckley A, Hook S. Barriers to the Uptake of Tickborne Disease Prevention Measures: Connecticut, Maryland 2016-2017. Journal Of Public Health Management And Practice 2024, 31: e52-e60. PMID: 39321400, DOI: 10.1097/phh.0000000000002033.Peer-Reviewed Original ResearchPersonal safety concernsPreventive measuresBarriers to consistent usePublic health programsLogistic regression modelsHealth programsTickborne diseasesDisease prevention measuresDemographic variablesPrimary barrierOutdoor activitiesTick checksDescriptive analysisOnline surveyRegression modelsSafety concernsCost concernsNatural pesticidesIncreased uptakePreventionBarriersTick habitatsSurveyConnecticutConcerns
2023
Operational Considerations for Using Deer-Targeted 4-Poster Tick Control Devices in a Tick-borne Disease Endemic Community
Hornbostel V, Meek J, Hansen A, Niesobecki S, Nawrocki C, Hinckley A, Connally N. Operational Considerations for Using Deer-Targeted 4-Poster Tick Control Devices in a Tick-borne Disease Endemic Community. Journal Of Public Health Management And Practice 2023, 30: 111-121. PMID: 37566802, PMCID: PMC10840788, DOI: 10.1097/phh.0000000000001809.Peer-Reviewed Original ResearchConceptsEndemic areasFuture public health interventionsPublic health interventionsDisease-endemic areasPublic health agenciesEndemic communitiesHealth interventionsCommunity settingsCommunity-wide approachEffectiveness studiesMonthly costHealth agenciesTick-borne diseasesLone star tickPersonal protectionAcceptability of 4-poster deer treatment devices for community-wide tick control among residents of high Lyme disease incidence counties in Connecticut and New York, USA
Nawrocki C, Piedmonte N, Niesobecki S, Rowe A, Hansen A, Kaufman A, Foster E, Meek J, Niccolai L, White J, Backenson B, Eisen L, Hook S, Connally N, Hornbostel V, Hinckley A. Acceptability of 4-poster deer treatment devices for community-wide tick control among residents of high Lyme disease incidence counties in Connecticut and New York, USA. Ticks And Tick-borne Diseases 2023, 14: 102231. PMID: 37531890, PMCID: PMC10883357, DOI: 10.1016/j.ttbdis.2023.102231.Peer-Reviewed Original ResearchEstimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023
Dalton A, Diallo A, Chard A, Moulia D, Deputy N, Fothergill A, Kracalik I, Wegner C, Markus T, Pathela P, Still W, Hawkins S, Mangla A, Ravi N, Licherdell E, Britton A, Lynfield R, Sutton M, Hansen A, Betancourt G, Rowlands J, Chai S, Fisher R, Danza P, Farley M, Zipprich J, Prahl G, Wendel K, Niccolai L, Castilho J, Payne D, Cohn A, Feldstein L, Group C, Group C, Saadeh K, Snyder R, Anderson M, Anguiano V, Nadle J, Rothrock G, Jones S, Duval L, Herlihy R, Stringer G, Weber R, Phan Q, Sosa L, Meek J, Lee M, Morrow A, Willut C, Carlson J, Kamis K, Nishiyama M, Simien G, Colasanti J, van der Woude T, Archer R, Finn L, Lam J, Moulton B, Peterson E, Bolan R, Garcia-Lopez G, Como-Sabetti K, Ruff A, Schneider D, Robinson T, Anderson B, Engesser K, McGuire S, Rowe A, Pride C, Mitchell J, Tourkina Y, Cieslak P, Fill M, Wiedeman C, Dumyati G, Felsen C, Lewnard J, Akoko B, Mansilla-Dubon K, Ndi D, Talbot H, Tiwari S, Wyatt D. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 553-558. PMID: 37200229, PMCID: PMC10205167, DOI: 10.15585/mmwr.mm7220a3.Peer-Reviewed Original ResearchConceptsAdjusted vaccine effectivenessVaccine effectivenessCase-control studyFull vaccinationEmerging Infections Program sitesEmergency use authorizationDuration of protectionPrevention of smallpoxImmunocompetent participantsImmunocompromised participantsControl patientsImmunization PracticesPartial vaccinationIntradermal injectionSubcutaneous injectionVaccinationMonkeypox casesAdministration routeDrug AdministrationVaccine accessLaboratory capacityTransgender adultsVaccineTransgender personsAdvisory Committee
2022
Early Release - Economic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014–2016 - Volume 28, Number 6—June 2022 - Emerging Infectious Diseases journal - CDC
Hook S, Jeon S, Niesobecki S, Hansen A, Meek J, Bjork J, Dorr F, Rutz H, Feldman K, White J, Backenson P, Shankar M, Meltzer M, Hinckley A. Early Release - Economic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014–2016 - Volume 28, Number 6—June 2022 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2022, 28: 1170-1179. PMID: 35608612, PMCID: PMC9155891, DOI: 10.3201/eid2806.211335.Peer-Reviewed Original ResearchConceptsTotal societal costsSocietal costsLyme diseasePatient costsInfectious Diseases journal - CDCMean patient costMean societal costLyme disease endemic stateTotal patient costsCost-effectiveness analysisDisseminated diseaseProspective studyEarly diagnosisIncidence areaDiseaseEffective preventionProbable diseaseDemographic factorsPrevention methodsComprehensive economic evaluationEconomic evaluationPatientsVaccineIllnessDiagnosisDesigning an Intervention Trial of Human-Tick Encounters and Tick-Borne Diseases in Residential Settings Using 4-Poster Devices to Control Ixodes scapularis (Acari: Ixodidae): Challenges for Site Selection and Device Placement
Connally NP, Rowe A, Kaufman A, Meek JI, Niesobecki SA, Hansen AP, White J, Nawrocki C, Foster E, Hinckley AF, Eisen L. Designing an Intervention Trial of Human-Tick Encounters and Tick-Borne Diseases in Residential Settings Using 4-Poster Devices to Control Ixodes scapularis (Acari: Ixodidae): Challenges for Site Selection and Device Placement. Journal Of Medical Entomology 2022, 59: 911-921. PMID: 35294011, PMCID: PMC10903785, DOI: 10.1093/jme/tjac027.Peer-Reviewed Original ResearchEconomic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014–2016
Hook SA, Jeon S, Niesobecki SA, Hansen AP, Meek JI, Bjork JKH, et al. Economic burden of reported Lyme disease in high-incidence areas, United States, 2014–2016. Emerg Infect Dis. 2022 Jun. https://doi.org/10.3201/eid2806.211335Peer-Reviewed Original Research
2021
Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States
Hook SA, Hansen AP, Niesobecki SA, Meek JI, Bjork JKH, Kough EM, Peterson MS, Schiffman EK, Rutz HJ, Rowe AJ, White JL, Peel JL, Biggerstaff BJ, Hinckley AF. Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States. Vaccine 2021, 40: 298-305. PMID: 34895785, PMCID: PMC11705932, DOI: 10.1016/j.vaccine.2021.11.065.Peer-Reviewed Original ResearchConceptsLyme disease vaccineDisease vaccineSurvey-weighted descriptive statisticsMultivariable multinomial logistic regression modelsCross-sectional studyLyme disease incidenceHigh incidence areaCross-sectional surveyLogistic regression modelsSafety concernsMultinomial logistic regression modelsVaccine uptakeAdults 45Vaccine parametersVaccine candidatesVaccine attitudesPrevention optionsHealthcare providersWeb-based surveyVaccineSociodemographic characteristicsIncidence areaLyme diseaseDisease incidenceIncidenceInterim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021.
Pilishvili T, Fleming-Dutra KE, Farrar JL, Gierke R, Mohr NM, Talan DA, Krishnadasan A, Harland KK, Smithline HA, Hou PC, Lee LC, Lim SC, Moran GJ, Krebs E, Steele M, Beiser DG, Faine B, Haran JP, Nandi U, Schrading WA, Chinnock B, Henning DJ, LoVecchio F, Nadle J, Barter D, Brackney M, Britton A, Marceaux-Galli K, Lim S, Phipps EC, Dumyati G, Pierce R, Markus TM, Anderson DJ, Debes AK, Lin M, Mayer J, Babcock HM, Safdar N, Fischer M, Singleton R, Chea N, Magill SS, Verani J, Schrag S, Vaccine Effectiveness Among Healthcare Personnel Study Team. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021. MMWR Morb Mortal Wkly Rep 2021, 70: 753-758. PMID: 34014909, DOI: 10.15585/mmwr.mm7020e2.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
News
Get In Touch
Contacts
Mailing Address
Yale School of Medicine
310 Cedar Street, PO Box 208063
New Haven, CT 06510
United States